| SUPPORT | Semaglutide for people with obesity and resistant hypertension (SUPPORT): a randomised, parallel group, integrated, multicentre clinical trial
| Clinical Trial (SUPPORT WEBSITE)
(HRB Study Info)
| Trinity College Dublin | Non-Commercial: Academic |
| Redefine 2 | "Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide
s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or
obesity and type 2 diabetes"
| Clinical Trial (NCT05394519) | Novo Nordisk | Commercial: Industry
|
| Redefine 3
| The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease
| Clinical Trial (NCT05669755) | Novo Nordisk | Commercial: Industry
|
| PKD Registry | Pyruvate Kinase Deficiency Global Longitudinal Registry | Clinical Trial (NCTO3481738) | Agios | Commercial : Industry |
